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Summary. Miltefosine, an alkylphosphocholine structurally 
related to alkyllysophospholipids showed highly selective 
antitumour activity against he hormone-sensitive variant of 
the s.c. transplantable MXT mouse mammary adenocarcino- 
ma, the ovary-dependent MXT (M3.2), whereas it was inac- 
tive against he hormone-insensitive MXT (M3.2) OVEX 
variant. A dose of 32 mg/kg miltefosine p.o. daily for 5 
weeks was well tolerated. Histopathological evaluation gave 
no signs of gastroenteral toxicity. After therapy the microar- 
chitecture of the MXT (M3.2) tumours changed from that of  
a moderately differentiated adenocarcinoma to that of an 
anaplastic mammary carcinoma. A dose of 16 mg/kg milte- 
fosine p.o. daily, though in effective per se, enhanced the an- 
titumour activity of suboptimal i.p. doses of cisplatin and the 
hormone-like platinum analogue [meso-l,2-bis(2,6-dichlo- 
ro-4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II). 
Furthermore, it was shown, that miltefosine exhibited no (an- 
ti)hormonaI properties. However, the mechanism of action of 
miltefosine remains unclear. 
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Introduction 
Miltefosine, anew alkylphosphocholine, shows high in vivo 
antitumour activity against he autochthonous experimental 
hormone-sensitive dimethylbenz[a]anthracene- and the 
methylnitrosourea-induced rat mammary tumour models 
(Muschiol et al. 1988; Hilgard et al. 1990a,b) rather than 
against transplantable tumours (Scherf et al. 1987; Hilgard et 
al. 1988; Yanapirut et al. 1991) with the exception of the hu- 
Abbreviation. Complex A, [meso- l,2-bis(2,6-dichloro-4-hydroxyphe- 
nyl)ethylenediamine]dichloroplatinum(II) 
Correspondence to:T. Sprul3 
man KB squamous epithelial carcinoma xenografts in nude 
mice (Hilgard et al. 1991). 
In phase I clinical studies the topical application of milte- 
fosine led to the reduction of skin metastases ofpatients uf- 
fering from breast cancer (Unger et al. 1990a,b; ten Bokkel 
Huinink et al. 1992). 
Various hypotheses on the mechanism of action of milte- 
fosine, such as interference with phospholipid metabolism 
(Haase t al. 1991), inhibition of protein kinase C (Shoji et al. 
1991; f]berall et al. 1991) or Na/K-ATPase (Zheng et al. 
1990) have been proposed. 
In contrast to the structurally related alkyllysophospholi- 
pids (Andreesen and Munder 1990) miltefosine lacks immu- 
nomodulatory activity (Hilgard et al. 1991), whereas modu- 
lation of differentiation processes eems to be involved in 
tumour egression caused by alkyllysophospholipids (Hon- 
ma et al. 1981; Honma et al. 1983) and miltefosine, respec- 
tively (Hochhuth et at. 1990; Hitgard et aL 1989). However, 
there is controversy if miltefosine is an inducer (Hochhuth et 
al. 1990) or inhibitor (Shoji et al. 1991) of tumour cell differ- 
entiation. 
Very recently in vitro synergism of ilmofosine, a 1-S-thio- 
etheralkyllysophospholipid derivative, and various antineo- 
plastic drugs has been reported (Weisbrod et al. 1990; 
Herrmann et al. 1992a). De Cesare et al. (1992) found that 
the in vivo antitumour activity of cisplatin against human 
lung tumour xenografts was also significantly enhanced by 
ilmofosine. On a murine fibrosarcoma model a similar in vi- 
vo synergism of ilmofosine and cisplatin was observed by 
Herrmann et al. (1992b). 
In order to investigate the contribution of differentiation 
and possible synergism of miltefosine and platinum com- 
plexes we chose the subcutaneously transplantable MXT 
mouse mammary carcinoma model existing in two variants 
(Watson et al. 1977, 1980). The hormone-independent MXT 
(M3.2) OVEX tumour is anaplastic whereas the ovary-de- 
pendent MXT (M3.2) variant is a moderately towell-differ- 
entiated adenocarcinoma. Histopathological evaluation in- 
cluding morphometric analysis of hormone-dependent MXT 
tumours hould give further insight into the mode of action 
of miltefosine. 
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Materials and methods 
In vitro studies 
Cell lines and culture conditions. The MXT + and MXT cell lines were 
established after mechanical and enzymatic disintegration of vital tu- 
mour ,,tissue" of the ovary-dependent MXT (M3.2) and the hormone-in- 
sensitive variant MXT (M3.2) OVEX grown in untreated B6D2F~ mice 
(Beckenlehner 1991). The cells were maintained inRPMI-1640 medium 
(Sigma, Mfinchen) containing additional 0.6g/i L-glutamine (i.e. 
0.9 g/I), 2.0 g/I NaHCO 3, 10% fetal calf serum (Gibco, Eggenstein) and 
50 mg/i gentamycin (Sebio, Waichsing). The hormone-sensitive MXq ~ 
variant required 100 ng/1 oestradiol (Sigma, Mtinchen) supplementa- 
tion, whereas MXT- cells were maintained without oestradiol. The cells 
were serially passaged following trypsinization using trypsin 
(0.05%)/EDTA (0.02%) (Boehringer, Mannheim) and cultured in a wa- 
ter-saturated atmosphere of 95% air and 5% carbon dioxide at 37 ~ C in 
75-cm 2culture flasks (Costar, Tecnomara, Fernwald). 
Chemosensitivity esting. For determining the antitumour activity of 
miltefosine in vitro a standardized kinetic microassay based on crystal 
violet staining was used. The technical details of the procedure and the 
method of evaluation of drug action have been discussed recently (Bern- 
hardt et al. 1992). In brief: cells were seeded (100 ~/well) in 96-well 
flat-bottomned microtitration plates (Costar, Tecnomara, Fernwald) at 
an appropriate density of approximately 15 cells/microscopic field 
(magnification 320x). After 42-48 h the culture medium was removed 
by suction and replaced by fresh medium (200 gl/well) containing milte- 
fosine or vehicle (double-distilled water). Miltefosine was added as a 
1000-fold concentrated stock solution. On every plate 16 wells served as 
controls and 16 wells were used for each drug concentration. After var- 
ious times of incubation the cells were fixed with glutaraldehyde 
(Merck, Darmstadt) and stored in a refrigerator. At the end of the exper- 
iment all plates were stained with crystal violet (Serva, Heidelberg) si- 
multaneously. Absorbance was measured at 578 nm using a Biotek 309 
Autoreader (Tecnomara, Fernwald). Processing procedure, data analysis 
and evaluation were performed as described (Reile et al. 1990; Bern- 
hardt et ai. 1992). Results are presented as plots of absorbance or cor- 
rected treated/control (T/C) values versus time of incubation according 
to: T/C~o ~(%) = (T-Co)/(C-Co) x 100, where T is the absorbance of the 
treated cells, C is the absorbance of the controls, and C o is the absor- 
bance of the cells at the time when drug was added (t=-0). 
In vivo studies 
Drugs. Miltefosine (see Fig.l) and cisplatin were gifts from Asta Med- 
ica (Frankfurt/M.). Tamoxifen citrate was purchased from Sigma (M/in- 
chen). The [meso-l,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenedia- 
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Fig. 1. Sl]'ucture of mJ]tefosine, [meso-1,2-bis(2,6-dichloro-4-hydroxy- 
phenyl)ethylenediamine]dichloroplatinum(II) (co plex A), and cispla- 
tin 
mine]dichloroplatinum(II) complex (see Fig. 1, complex A) was synthe- 
sized and characterized asdescribed by Karl et al. (1988). 
Drug preparations. The vehicle for the platinum complexes and tamox- 
ifen citrate was polyethyleneglycol 400 (PEG)/1.8% NaC1 (1:1). These 
drugs were administered s.c. in an injection volume of 0.1 ml/20 g body 
weight as solution or suspension. Miltefosine was dissolved in double- 
distilled water and administered p.o. in a volume of 0.2 ml/20 g body 
weight. 
Animals and housing conditions. For all experiments with the MXT mu- 
rine mammary carcinomas, 8-week-old female B6D2F t mice (Charles 
River Wiga, Sulzfeld) were used. Uterine weight ests were carried out 
with 21-day-old female NMRI mice (Charles River Wiga, Sulzfeld). 
Animals were housed in Macrolon cages (size III; Ehret, Emmendingen) 
at an ambient temperature of 21 ~ C and with a 12 h light/dark cycle. The 
animals were fed with laboratory animal chow (H 1003; Alma, Kemp- 
ten) and water was provided ad libitum. 
Tumours, transplantation procedure, treatment schedule, 
and evaluation of drug effects 
Ovary-dependent MXT (M3.2) and hormone-insensitive MXT (1143.2) 
OVEX tumours. A detailed escription of the MXT variants used in this 
study and their growth characteristics have been published recently 
(Spml5 et a1.1991). 
Experimentalprotocol. On day 0 (after s.c. implantation ofabout 2-ram 3
tumour pieces into the region of the fight thoracal mammary fat pad) the 
animals were randomly assigned to groups of ten. Treatment was started 
on day 1 by injecting the platinum complexes, tamoxifen, and vehicle 
(PEG/saline) s.c. into the left flank, three times a week. Therapy with 
miltefosine and vehicle (double-distilled water) started on day 1 with the 
administration f the solutions p.o. with a gastro-oesophageal tube. Hor- 
mone dependence of the MXT (M3.2) tumour was checked by ovariec- 
tomy (on day 1) and tamoxifen treatment (Sprul3 et al. 1991). 
Evaluation of drug effects. Parameters for evaluating antitumour activi- 
ty were mean tumour area (ram 2) in the course of MXT (M3.2) and MXT 
(M3.2) OVEX experiments, and mean tumour wet mass at the end of the 
MXT (M3.2) experiments. Tumour area was calculated as the product of 
two perpendicular diameters, one measured across the greatest width. 
Determination of relative uterotrophic activity. Relative uterotrophic 
activity of miltefosine was determined by p.o. administration f differ- 
ent doses of the compound to 21-day-old female NMRI mice (Charles 
River Wiga, Sulzfeld). Three days after treatment (on day 4) the uteri 
were fixed in Bouin's solution for 24 h. Thereafter the uteri were clean- 
ed from adhering fat and connective tissue, and dried at 100 ~ C. Utero- 
trophic activity is defined as uterine dry mass (rag) divided by body 
mass (g). The mean uterotrophic activity of the test group divided by the 
mean uterotrophic activity of the corresponding control group, multi- 
plied by 100, gives the relative uterotrophic activity of a compound. 
Histology and morphometric analysis of the tumours. For histological 
documentation a d morphometric analysis the tumours were fixed in 
Bouin's solution. Paraffin sections (5 ~xm) were stained according to the 
method of Masson and Goldner modified by Jerusalem. The nuclear ar- 
eas of turnout cells were measured using an Olympus BH-2 microscope 
with a 60 • SPlanApo (oil) objective (Olympus Optical Co. Ltd., Tokyo, 
Japan). The microscopic mage was focused through aNFK 2.5 • photo- 
eyepiece to a Panasonic F10 CCD videocamera (Matsushita Communi- 
cation Industrial Co., Osaka, Japan). For image analysis the video signal 
was transformed in a PIP-512/1024A video digitizer board (Matrox 
Electronic Systems Ltd., Quebec, Canada) installed in an Olivetti M24 
personal computer (Ivrea, Italy) and visualized on a Sony PVM-1371 
QM video monitor (Tokyo, Japan). The nuclei were encircled with a 
mouse and the nuclear areas were automatically calculated using an im- 
age-processing program written in TURBO PASCAL. Three tumours 
per treatment group were morphometrically analysed. Solid, non-necro- 
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tic tumour egions from the abdominal side of the s.c. growing tumour 
were evaluated by measuring both 100 nuclei from highly differentiated 
structures and 100 nuclei from undifferentiated carcinoma cells. 
Estimation of gastrointestinal toxicity. At the end of the MXT experi- 
ments animals were dissected. The tumour and the pars descendens of
the duodenum of three animals per treatment group were fixed in 
Bouin's olution for histological evaluation. 
Statistics. The P values were calculated according to the Mann-Whitney 
U-test (Sokal and Rohlf 1987). 
Resul ts  
Chemosensitivity of MXT- and MXT + cells against 
miltefosine invitro 
The effect of three concentrations of miltefosine (1, 10 and 
100 JaM) on the hormone-independent MXT- and the hor- 
mone-sensitive MXT + breast cancer cell line is demonstrated 
in Fig. 2. On the MXT- variant all three concentrations of
miltefosine were ineffective (cf. Fig. 2A), whereas tumour 
cell proliferation of the MXT + cell line was strongly inhibited 
at the 100 gM dose (Fig. 2B). 
Effect of miltefosine on the MXT (M3.2) OVEX 
tumour in vivo 
Doses of 16 mg/kg and 32 mg/kg miltefosine (daily, p.o.) did 
not inhibit the proliferation of the hormone-independent 
MTX (M3.2) OVEX tumour. 
Effect of miltefosine on the MXT (M3.2) tumour in vivo 
The hormone dependence of the MXT (M3.2) mammary car- 
cinoma was demonstrated by strong inhibition of turnout 
growth by the anti-oestrogen tamoxifen (8 mg/kg, three 
times weekly, s.c.) and by ovariectomy on day 1 after tumour 
transplantation (Fig. 3A). Growth of this tumour was also de- 
creased by miltefosine treatment at a dose of 32 mg/kg (dai- 
ly, p.o.), whereas a dose of 16mg/kg was ineffective 
(Fig. 3B). 
Gastrointestinal toxicity of miltefosine 
Presumably miltefosine was non-toxic to the gastrointestinal 
tract, since the dissection of the mice showed no macroscop- 
ic changes. Histological examination revealed no alterations 
of mucosal cells of the pylorus and of the duodenum descen- 
dens that might have been caused by perorally administered 
miltefosine. 
Oestrogenic and anti-oestrogenic a tivity of miltefosine 
Since miltefosine was only active on the hormone-sensitive 
MXT variant (both in vitro and in vivo) we evaluated possi- 
ble hormonal (i.e. uterotrophic or antiuterotrophic) activities 
of this alkylphosphocholine using the uterine weight test. 
Doses of 4 mg/kg, 8 mg/kg, 16 mg/kg, and 32 mg/kg milte- 
fosine were administered to 21-day-old NMRI mice per- 
orally. The uterine weight test gave no indication for hor- 
monal activity of miltefosine on the uterus of immature mice. 
Uterine weight tests at the end of MXT (M3.2) experiments 
also gave no indication of (anti)hormonal ctivity of miltefo- 
sine on the uterus of adult mice. 
Combination therapy of the MXT (M3.2) tumour with milte- 
fosine and platinum complexes 
Cisplatin and the hormone-like platinum complex A were 
administered at suboptimal doses (3 ~mol/kg, three times 
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Fig. 2A,B. Effect of miltefosine treatment on the proliferation of two subtypes of the murine MXT mammary carcinoma invitro. Plots of corrected T/C 
values versus time of incubation. 9 1 N14; [5, 10 pM;/',, 100 laM miltefosine. - - -, The growth of the (distilled water) controls (0). A MXT- cell line 
(in passage 26) derived from the hormone-independent MXT (M3.2) OVEX tumour. B MXT + cell line (in passage 32) derived from the ovary-depen- 
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Fig. 3A-C. Growth curves of subcutaneously implanted ovary-dependent MXT (M3.2) mammary carcinoma in female B6D2F 1 mice. A Hormone de- 
pendence of this tumour was demonstrated by strong tumour growth inhibition after ovariectomy (O) and tamoxifen (8 mg/kg, s.c. 3 times weekly) 
treatment (~) in comparison with untreated control (O). Inset shows typical increase in body mass of ovariectomized animals. B Miltefosine at a con- 
centration of 16 mg/kg, p.o. (A) did not influence tumour growth compared with the p.o. control (B). A dose of 32 mg/kg, p.o. miltefosine (A) signif- 
icantly (P<0.01 ) inhibited MXT (M3.2) turnout growth. During the course of the experiment the body masses of the mice remained almost unchanged. 
C Hormone-like platinum complex A (C3) as well as cisplatin (O) inhibited MXT (M3.2) tumours at equimolar doses of 3 gmol/kg, s.c. (three times 
weekly) significantly (P<0.01, compared with controls in A). When miltefosine at the ineffective dose of 16 mg/kg p.o. was given in combination with 
these platinum complexes (with complex A, i ;  with cisplatin, tJ) their antitumour activity was significantly enhanced (complex A + miltefosine: 
P<0.01; cisplatin + miltefosine: P<0.05). Inset shows strong increase in body mass in animals treated with platinum complex A 
weekly, s.c.) (Fig. 3C) (cf. Sprug et al. 1990). Additional 
miltefosine therapy at a dose of 16 mg/kg, which was inef- 
fective as monotherapy in this tumour experiment, could sig- 
nificantly enhance antitumoral effects of these platinum 
complexes (Fig. 3C) (Sprug et al. 1989). 
These results were confirmed by determining mean tu- 
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Fig. 4. Wet weights of MXT (M3.2) tumonrs at the end of experiment 
(see Fig.3). At a dose of 16 mg/kg (MIL 16) miltefosine alone was inef- 
fective but reduced tumour wet masses in combination with cisplatin 
(CDDP + MILl6) significantly with P<0.01). In combination with the 
hormone-like platinum complex A (14 + MILl6) tumour eduction was 
also significant (P<0.05). The doses of cisplatin and complex A were 
3 gmol/kg.(three times weekly, s.c.) 
Histology of MXT (M3.2) tumours after treatment with 
miltefosine alone and in combination with platinum com- 
plexes 
All s.c. implanted tumours were encapsulated bycollagen fi- 
bres and no infiltrative or invasive growth could be observed, 
irrespective of therapy. The histology of untreated MXT 
(M3.2) tumours howed a moderately differentiated a eno- 
carcinoma. Epithelial cells were arranged in irregular sheets 
or ductular structures with little stroma. The detail in Fig.5A 
shows moderate differentiation towards ductal or papillary 
formations. In contrast o the original MXT tumour de- 
scribed by Watson et al. (1977), the MXT (M3.2) variant 
used in our studies was less differentiated, but exhibited a
similar esponse to hormonal therapy. 
Treatment with miltefosine (32 mg/kg, p.o.) led to a mar- 
ked loss of differentiated tumour structures. The histological 
appearance of the carcinoma (Fig. 5B) resembled that of the 
hormone-independent MXT variant MXT (M3.2) OVEX, 
which is a fast-growing anaplastic arcinoma. Only scanty 
stroma appeared between the irregularly arranged tumour 
cells. 
The characteristic changes in tumour microarchitecture 
caused by the hormone-like platinum complex A were an in- 
crease in ductular structures lined by a single layer of epithe- 
lial cells. Irregularly organized epithelial carcinoma cells 
formed sheets between the ductular structures (Fig. 5C). 
Combination therapy with miltefosine and the platinum 
complex A completely changed the microarchitecture of the 
MXT (M3.2) tumour (Fig. 5D). Most of the tumour epitheli- 
al cells were arranged in elongated uctular structures that 
were formed by one single layer of epithelium. Undifferenti- 
ated tumour parts were rare and stroma was scanty. 
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Fig. 5A-D. Histology of the MXT (M3.2) tumour after different therapies. Masson-Goldner-Jerusalem stained, l x 180. A Subcutaneously growing 
tumour of an untreated mouse resembles a moderately differentiated adenocarcinoma. B Treatment with miltefosine (32 mg/kg) l d to an almost com- 
plete loss of differentiated tumour structures. After treatment the undifferentiated tumour is similar to the hormone-independent MXT (M3.2) OVEX 
carcinoma. C An increase in epithelial tumour cells, organized in large ductular structures, is typical for tumours treated with hormone-like platinum 
complex A. Undifferentiated tumour cell fo mations appear between these highly differentiated structures. D Combination therapy with platinum com- 
plex A and miltefosine led to an almost complete loss of undifferentiated formations. Mostof the tumour ceils are organized in large elongated ductu- 
lar structures 
D 
Morphometric analysis of MXT (M3.2) tumours after treat- 
ment with miltefosine alone and in combination with plati- 
num complexes 
Morphometric analysis of tumour cell nuclei was carried out 
to quantify morphological changes of nuclei from differenti- 
ated and from undifferentiated tumour cell populations. 
The differentiated tumour cell populations were epithelial 
cells forming acini or ductular structures, whereas irregularly 
arranged tumour cells represented anaplastic tumour areas. 
In untreated controls, both cell types had a mean nuclear area 
of about 30 gm 2 (Fig. 6). Whereas miltefosine at a dose of 16 
mg/kg did not change these parameters, a dose of 32 mg/kg 
led to an increase in nuclear size of undifferentiated tumour 
cell formations. Typical for cisplatin was an increase in nu- 
clear area of both tumour cell types. 
Only a slight increase in nuclear area was registered after 
treatment with platinum complex A. The combination of 
miltefosine and cisplatin did not change these morphometric 
parameters ignificantly, i.e. miltefosine, administered in 
combination therapy at a concentration of 16 mg/kg, did not 
affect the size of tumour cell nuclei. 
Discussion 
In the literature several modes of action of miltefosine and 
the structurally related alkyllysophospholipids ncluding di- 
rect cytotoxic activity (Berdel et al. 1981), inhibition of 
phosphatidylcholine biosynthesis (Haase et al. 1991), induc- 
tion of differentiation (Hilgard et al. 1989) and interference 
with signal transduction processes, especially inhibition of 
protein kinase C (Uberall et al. 1991), are discussed. How- 
ever, the precise mechanism of the tumour-inhibiting activity 
of mittefosine is not yet understood. This motivated us to in- 
vestigate further the activity of miltefosine against MXT 
mouse mammary carcinomas in vitro and in vivo. 
Chemosensitivity experiments showed a striking speci- 
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Fig. 6. Morphometric data from untreated MXT (M3.2) tumours how 
that urnout cell nuclei from highly differentiated structures (open col- 
umns) and nuclei from undifferentiated cell formations (hatched col- 
umns) have similar sizes. Cisplatin therapy (CDDP) leads to typical en- 
largement ofall tumour cell nuclei, while miltefosine therapy (32 mg/kg 
p.o., MIL32) only increased the size of the nuclei of the undifferentiated 
tumour areas. At a dose of 16 mg/kg p.o. (MILl6) miltefosine did not in- 
fluence nuclear areas of tumour cells when combination therapies with 
platinum complexes were performed. A, platinum complex A
MXT § a dose where the hormone-independent MXT- vari- 
ant was not affected. The cytocidal dose (Fig. 2) of 100 gM 
may seem very high, but K6tting et al. (1992) reported thera- 
peutic serum levels of 120 gM miltefosine in rats and Unger 
et al. (1990a) measured steady-state plasma levels of 
100-200 ~xrnol/1 in patients 2 weeks after daily treatment 
with 50-200 mg miltefosine. 
In vivo the proliferation of the anaplastic MXT (M3.2) 
OVEX turnout was not inhibited by 32 mg/kg miltefosine 
whereas the ovary-dependent, moderately differentiated 
MXT (M3.2) tumour was significantly reduced. The lack of 
antitumoral ctivity of miltefosine against the hormone-inde- 
pendent MXT (M3.2) OVEX turnout in vivo is in accordance 
with the work of Muschiol et al. (1987) and Yanapirut et al. 
(1991). Since the MXT (M3.2) breast cancer model is ex- 
tremely sensitive to hormonal manipulation (SpruB et al. 
1991) this experiment could not exclude the possibility that 
tumour eduction was caused by some hormonal activity of 
miltefosine, although Hilgard et al. (1990a) suggested that 
the therapeutic activity of miltefosine was independent ofthe 
hormone receptor status of the turnout. We could clearly 
demonstrate, by the uterine mass test in the juvenile mouse, 
that miltefosine lacks (anti)oestrogenic a tivity. In contrast 
to previously reported results (Muschiol et al. 1987) we 
found no signs of gastrointestinal toxicity of miltefosine. The 
toxic effects reported by Muschiol et al. (1987) in Sprague- 
Dawley rats could not be observed in our experiments carried 
out with B6D2F 1 mice. Livers and spleens of the mice were 
macroscopically not affected and histological examinations 
showed no signs of toxic action to the gastrointestinal tract. 
A slight decrease in body mass during the course of the ex- 
periment was due to daily p.o. application, and not caused by 
drug action. 
Whereas Hilgard et al. (1989) demonstrated induction of 
differentiation i dimethylbenz[a]anthracene-induced mam- 
mary turnouts of rats, the differentiated MXT (M3.2) tu- 
rnouts were transformed to anaplastic arcinomas after the 
treatment with miltefosine in vivo. Modulation of differenti- 
ation seems to be a very complex process and miltefosine can 
paradoxically induce or inhibit differentiation depending on 
the special nature of the tumour investigated. While Hoch- 
huth et al. (1990) induced differentiation by treating U937 
cells with a phorbol ester or with miltefosine, Shoji et al. 
(1991) inhibited phorbol-ester-induced differentiation of 
HL60 cells by miltefosine treatment. 
Morphological changes uch as formation of ,,apoptotic 
bodies", pyknosis, and lysis of nuclei in MXT (M3.2) tu- 
mours are considered typical of apoptosis (Tomei and Cope 
1991). Szende t al. (1990) postulated, that these changes are 
associated with hormonally induced turnout regression, 
whereas in our experiments formations like apoptotic bodies, 
pyknosis and specific lysis of turnout cell nuclei were equal- 
ly distributed in turnout sections of the controls and all treat- 
ment groups. In our opinion apoptosis, a hypothetically dis- 
tinct type of cell death (Kerr and Harmon 1991), does not 
contribute to tumour egression either by miltefosine, plati- 
num complexes or tamoxifen or by ovarectomy. 
Weisbrod et al. (1990) found additive or synergistic anti- 
tumoral effects by combining ilmofosine with a variety of 
cytostatics including cisplatin in vitro. In our in vitro experi- 
ments a combination of cisplatin and miltefosine did not en- 
hance platinum cytotoxicity against human breast (MDA- 
MB-231, MCF-7) and ovarian cancer (SK-OV-3) cell lines 
(data not shown). On the contrary, in vivo combination ther- 
apy of miltefosine with cisplatin and a hormone-like plati- 
num complex led to a significant enhancement of the antitu- 
mour activity of these compounds on MXT M3.2 mammary 
carcinoma. These combinations were non-toxic. 
Muschiol et al. (1988) reported an accelerated turnout 
growth of methylnitrosourea-induced rat mammary carcino- 
mas treated with a combination of tamoxifen and miltefo- 
sine. This combination therapy in rats caused severe toxic ef- 
fects that even led to death of the animals. 
Turnout-infiltrating leucocytes, which massively invade 
many experimental rodent turnouts during regression 
(Schreiber 1989), were rarely observed in MXT mammary 
carcinomas after miltefosine therapy. Since xenografted tu- 
rnouts in nude mice could effectively be treated with miltefo- 
sine (Voegeli et al. 1990; Hilgard et al. 1991) there is no ex- 
perimental evidence that miltefosine action is mediated by 
the host's immune system. 
These findings are consistent with our results obtained 
after implantation of the ovary-dependent MXT (M3.2) 
mammary carcinoma into T-cell-deficient NMRI mice. A 
daily dose of 32 mg/kg p.o. of miltefosine led to about 60% 
turnout inhibition. 
From our in vitro and in vivo experiments using the two 
variants of the MXT mouse mammary carcinoma we con- 
clude, that no hormonal effects can be involved in the mech- 
anism of action of miltefosine. Differences other than hor- 
mone sensitivity or type of differentiation of these turnout 
variants, such as inhibition of protein kinase C, must be re- 
148 
sponsible for the highly specific activity against the moder- 
ately to well-differentiated MXT (M3.2) mammary adeno- 
carcinoma of the B6D2F~ mouse. 
Remark: Meanwhile a clinical study by Winkelmann et al. (1992) de- 
monstrated dose-limiting gastrointestinal toxicity of p.o. treatment with 
ilmofosine. The authors conclude that treatment with oral ilmofosine is 
not effective in patients with liver metastases due to various malignan- 
cies. 
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